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Abstract
Sjogren's syndrome (SS) is a complex autoimmune disease that primarily affects salivary and
lacrimal glands and is associated with high morbidity. Although the prevailing dogma is that
immune system pathology drives SS, increasing evidence points to structural defects, including
defective E-cadherin adhesion, to be involved in its etiology. We have shown that E-cadherin
plays pivotal roles in the development of the mouse salivary submandibular gland (SMG) by
organizing apical-basal polarity in acinar and ductal progenitors and by signaling survival for
differentiating duct cells. Recently, E-cadherin junctions have been shown to interact with
effectors of the Hippo signaling pathway, a core pathway regulating organ size, cell proliferation
and differentiation. We now show that Hippo signaling is required for SMG branching
morphogenesis and is involved in the pathophysiology of SS. During SMG development, a Hippo
pathway effector, TAZ, becomes increasingly phosphorylated and associated with E-cadherin and
α-catenin, consistent with the activation of Hippo signaling. Inhibition of Lats2, an upstream
kinase that promotes TAZ phosphorylation, results in dysmorphogenesis of the SMG and impaired
duct formation. SMGs from NOD mice, a mouse model for SS, phenocopy the Lats2-inhibited
SMGs and exhibit a reduction in E-cadherin junctional components, including TAZ. Importantly,
labial specimens from human SS patients display mislocalization of TAZ from junctional regions
to the nucleus, coincident with accumulation of extracellular matrix components, fibronectin and
CTGF, known downstream targets of TAZ. Our studies show that Hippo signaling plays a crucial
role in SMG branching morphogenesis and provide evidence that defects in this pathway are
associated with SS in humans.
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Sjogren's syndrome (SS) is a disabling autoimmune disease of the salivary and lacrimal
glands whose manifestations include hypo-salivation and ocular dryness (1). The central
dogma in SS and autoimmunity, in general, has been that the T cell receptor determines
target specificity and that immune system pathology is the sole explanation for disease.
However, this dogma is increasingly challenged by the fact that in diabetes and SS-
associated neuropathology, structural defects often exist prior to the onset of autoimmune
disease (2-6). Further, recent findings in non-obese diabetic (NOD) mice, a mouse model for
SS, suggest a direct role for the tissue itself in disease targeting (7, 8). Since little is known
about the etiology of SS, identification of the molecular events that are essential for
development of the salivary gland and whose dysregulation gives rise to structural defects in
NOD mice that mimic SS in humans is critical.
Development of the salivary gland has been most extensively studied in the mouse
submandibular gland (SMG) as a model system. The SMG belongs to a group of epithelial
tissues that develop through branching morphogenesis, a process regulated by the reciprocal
cross talk between the epithelium and mesenchyme, as well as by interactions with the
endothelium and the neuronal system (9-16). The SMG has become a useful tool for the
identification of molecular events regulating this developmental process, in part, due to the
ability to grow early embryonic SMG organ cultures, which provides an excellent ex vivo
model that mimics branching morphogenesis in vivo (12, 15). Using this system, we have
identified E-cadherin, the primary epithelial cell-cell adhesion receptor that organizes
adherens junctions (AJs), as a principal regulator of morphogenetic changes during SMG
development. E-cadherin regulates branching morphogenesis by establishing apical-basal
polarity in acinar and ductal progenitors and by protecting differentiating duct cells within
newly forming ductal lumens from apoptotic death (16). However, cues that lie downstream
of E-cadherin in SMG development are poorly understood.
Recently, E-cadherin-mediated cell adhesion has been shown to influence the activity of the
Hippo pathway, a conserved signaling pathway critical for regulating cell fate, tissue
homeostasis and organ growth (17-20). In mammals, the primary downstream effectors of
the Hippo pathway are the paralogous proteins TAZ and YAP. The functions of TAZ and
YAP are determined by their nuclear-cytoplasmic localization, which is regulated by
phosphorylation. The Lats1 and Lats2 kinases are the primary kinases described to regulate
TAZ and YAP localization by promoting their phosphorylation on residues that induce
binding to 14-3-3, a family of conserved regulatory proteins that interact with cell polarity
and adhesion proteins to sequester TAZ and YAP in the cytoplasm. Lats kinase inhibition
promotes TAZ and YAP nuclear accumulation, subsequently inducing TAZ and YAP
activity as transcriptional regulators (18, 21).
Salivary glands and pancreatic islets from NOD tissues uniformly display lack of E-cadherin
adhesion in situ and altered cellular adhesion in isolated cells (8). Since Hippo signaling is
regulated by E-cadherin-mediated adhesion through binding to α-catenin and tight junction
associated Crumbs polarity complexes (22-25), we hypothesized that defects in this pathway
promote NOD dysfunction and SS phenotype in humans. In this study, we examine the
Hippo pathway in mouse SMG embryonic development and show that it has a role in E-
cadherin-mediated apical-basal polarity in differentiating acinar and ductal progenitors and
that it plays critical roles in secondary duct formation. We also provide evidence that
Enger et al. Page 2
Lab Invest. Author manuscript; available in PMC 2014 May 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tdefective Hippo signaling contributes to the structural defects in the NOD SMG and,
importantly, deregulated Hippo signaling is a feature of human SS.
Materials and Methods
Mouse strains
For mouse studies, CD-1 wild type and NOD mouse strains were used. The day the vaginal
plug was detected was considered embryonic day 0.5 (E 0.5). All animal experiments were
approved by the Institutional Animal Care and Use Committee at the Boston University
Medical Center.
Minor human salivary glands
Formalin fixed, paraffin embedded lower lip minor salivary glands were collected with a
written consensus from three different biobanks in Oslo, Norway. The Norwegian
Committee of Ethics approved the use of the biopsies in the study. To assure proper
diagnosis, an oral pathologist reevaluated all biopsies blindly using American-European
Consensus Criteria (AECC) criteria to determine the focus score (the number of focal
mononuclear cell infiltrates with ≥50 mononuclear cells per 4 mm2). Minor salivary glands
evaluated for SS, but not fulfilling AECC criteria, served as controls. Patients with SSA or
SSB autoantibodies, or patients diagnosed with secondary SS, were excluded as controls.
For each marker analyzed by immunostaining, a minimum of six biopsies from SS
compatible patients and six non-compatible controls were used.
SMG organ cultures
SMG salivary gland rudiments were dissected from embryos at E13.5-E18.5, cultured on
Whatman Nucleopore Track-etch filters (GE healthcare, Buckinghamshire, UK) and grown
in an air/medium interface at 37°C in a humidified 5% CO2 atmosphere (16). The filters
were placed on top of 200 μl media containing DMEM/F12 (ATCC, VA, USA)
supplemented with 150 μg/ml vitamin C, 50 μg/ml transferrin, 100 μg/ml penicillin and 100
μg streptomycin in 30 mm glass bottom microwell dishes (MatTek, MA, USA) with six
glands per filter. During transfection with small interfering RNA, penicillin and
streptomycin were omitted from the growth media. For functional studies using Lats2
siRNA, glands were photographed at 0, 24 and 48 h using a Nikon Eclipse TS100
microscope (Nikon, Tokyo, Japan). For analyses of SMGs treated with Lats2 siRNA, 23
silenced and 23 non-silenced glands were analyzed to measure the gland area and number of
buds using ImageJ software (version 1.45s).
Antibodies
Antibodies to TAZ, E-cadherin, fibronectin, IQGAP1 and β-catenin were purchased from
BD Transduction Laboratories, CA, USA. Two antibodies to α-catenin, one produced in
mouse and one produced in rabbit, were obtained from Sigma, MO, USA and BD
Transduction Laboratories, respectively. The antibody to phospho-YAP, also recognizing
phosho-TAZ, was obtained from Cell Signaling Technology, MA, USA. The antibody to
YAP, also recognizing TAZ, was purchased from Santa Cruz Biotechnology, CA, USA.
While these antibodies recognize both TAZ and YAP, the differences in the molecular
weights of TAZ (55 kDa) and YAP (65 kDa) make them easily distinguishable. Antibodies
to connective tissue growth factor (Ctgf), Ki67 and total YAP were purchased from Abcam,
MA, USA.
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Formalin fixed paraffin-embedded human labial salivary glands biopsies were cut into 4-6
μm sections using a Leica serial Microtome (Leica Instruments, Solms, Germany) and
placed on SuperFrost® Plus microscope slides (Thermo Scientific, MA, USA). Before
staining, each slide was rinsed in distilled water prior to heat induced epitope retrieval in a
microwave using 9:1 Retrievit-6 Target Retrieval Solution (Biogenex, CA, USA) and MilliQ
water. Slices were cooled for 20 min prior to overnight blocking in 10% goat serum (Sigma)
at 4°C. Sections were incubated in primary antibodies diluted in PBS-T (20mM Tris, 137
mM NaCl, 0.1% Tween 20, pH 7.6) with 10% BSA for 1 h at room temperature (RT). The
slides were washed in PBS-T before incubating in goat anti-mouse/rabbit AlexaFlour® 594
(Invitrogen, NY, USA) or goat anti-mouse/rabbit FITC tagged (Invitrogen) secondary
antibodies diluted at 1:100 in PBS-T, and counterstained for nuclei with DAPI (Invitrogen)
at RT for 30 min. The slides were then washed 3 times in PBS-T before mounting using
Vectashield (Vector Laboratories, CA, USA) and microscope cover glass (Fisher Scientific,
MA, USA). For negative controls, the primary antibodies were omitted.
For whole mount immunofluorescence of mouse SMGs, E13.5, E15.5 and E18.5 glands
were grown on filters for 2 h prior to fixation in 3.7% paraformaldehyde for 40 min at RT.
The glands were then washed in PBS and permeabilized using 0.1% Triton-X in PBS for 20
min (E13.5) or 40 min (E15.5 and E18.5) at RT. After permeabilization, the glands were
washed 3 times in PBS-T prior to overnight blocking in 10% goat serum, 10% BSA and
PBS-T at 4°C. Primary antibodies were diluted 1:100 in 10% BSA and PBS-T and incubated
for 3.5h at RT. The glands were washed in PBS-T before adding FITC-conjugated
secondary antibodies (Invitrogen) at 1:100 dilution in PBS-T for 1.5 h at RT. The secondary
antibodies were removed, and Rhodamine Phalloidin (Invitrogen) at 1:100 and TO-PRO®-3
iodide (Invitrogen) at 1:1000 were counterstained for F-actin and nuclei, respectively, for an
additional 30 min at RT. The glands were then washed overnight and mounted on
SuperFrost®Plus microscope slides (Thermo Scientific) using 15 μl Vectashield (Vector
Laboratories). The immunostained glands were then analyzed using a Zeiss LSM 510
confocal microscope as previously described (16).
Tissue extraction
SMGs were immediately frozen on dry ice following dissection and were kept at −80°C
prior to protein extraction. For preparation of total tissue lysates, SMGs were extracted in
OGT buffer (10 mM imidazole, 3 mM sodium pyrophosphate, 100 mM NaCl, 1% Triton X,
5 mM EDTA, 1 mM MgCl2, 45 mM n-Octyl β-D glucopyranoside) supplemented with a
protease inhibitor cocktail (Sigma) and 100 mM PMSF. Whole tissue lysates were used for
detection of selected proteins and protein complexes by immunoblot and
immunoprecipitation. Protein concentration was determined using the BCA assay (Thermo
Scientific).
Immunoblot and co-immunoprecipitation
For biochemical analyses, 10-15 glands from E13.5, 6-8 glands from E15.5 or 2-4 glands
from E18.5 were collected from the same litter and kept on dry ice prior to protein extraction
as described above. For each embryonic time point, 50 μg of protein was used with reducing
2x sample buffer (Sigma). The samples were heated at 95°C for 5 min before being
fractionated on 7.5% SDS-PAGE. The gel was electrophoretically transferred onto PVDF
membranes (Invitrogen) at 60V. The membrane was blocked for 1 h in 10% milk prior to
overnight incubation in primary antibody at 4°C, followed by 1 h incubation at 27°C using
secondary horseradish peroxidase-conjugated antibodies (Sigma). ECL plus detection
reagent (GE Healthcare) was used for visualization of bands, and quantification analysis of
band intensity was performed using ImageJ software (version 1.45s).
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was prepared from either E15.5 or E18.5 glands. Unspecific binding to IgG was removed by
pre-clearing with normal mouse IgG (Santa Cruz Biotechnology) for 1 h. Samples were
incubated with primary antibody for 2 h followed by incubation with protein agarose beads
(GE Healthcare) for 1 h as described previously (16, 26). Immunoprecipitates were
subjected to electrophoresis under either reducing or non-reducing conditions, as described
above.
RNA interference
Small interfering RNAs (siRNA) targeting Lats2 were obtained as SMART-pool™
sequences (Dharmacon, CO, USA) while the non-silencing negative control siRNA was
from Qiagen. To determine optimal siRNA concentrations, different amounts ranging from
100 to 400 nM were tested for various time periods. The most distinct phenotype was
observed using 400 nM siRNA at 48 h. From each mouse embryo, one gland was used for
silencing while the corresponding gland was used as a non-silencing control. Six glands
were placed on each filter and transfected using RNAiFect (Qiagen) with either 400nM of
siRNA targeting Lats2 or a non-silencing, scrambled control. BLOCK-iT™ Fluorescein
Oligo (Invitrogen) was co-transfected with Lats2 siRNA to mark transfection efficiency.
After transfection, glands were incubated at 37°C for 48 h and frozen in sterile tubes for
protein or RNA extraction or fixed in 3.7% paraformaldehyde prior to immunostaining.
RNA extraction and RT-PCR
RNA from SMGs was extracted using the Qiagen RNeasy Minikit, and cDNA was prepared
using SuperScript III (Invitrogen). Gene expression profiles were generated by normalizing
the Ct (threshold cycle number) of Lats2 with housekeeping gene 18S and by comparing the
gene expression of SMGs treated with silencing Lats2 siRNA (S) to non-silencing siRNA
(NS). Statistical analysis was performed using an unpaired sample t-test comparing mRNA
expression levels of Lats2 in NS controls to Lats2 siRNA treated glands from three different
RNA preparations.
Statistics
For immunoblot and co-immunoprecipitation assays, mean values from a minimum of
triplicate samples are reported ± SEM. All data were analyzed using unpaired sample t-tests.
Values of p<0.05 were considered significant.
Results
Expression and localization of the Hippo pathway effector TAZ during SMG embryonic
development
Mouse SMG development is initiated at embryonic day 11 (E11) as an epithelial thickening
that gives rise to a bud structure by E12.5 (Figure 1a, E12.5). During morphogenesis, the
initial bud grows and expands into the underlying mandibular mesenchyme while cells in the
stalk region reorganize to form a presumptive duct. The expansion of the bud into the
mesenchyme is accompanied by repetitive clefting and new bud formation, which is
coordinated with the extension of the primary duct into an array of secondary ducts leading
into the newly forming terminal buds. Throughout this process, regions of the developing
salivary epithelium undergo cytodifferentiation to produce a tree-like structure by E18.5
consisting of differentiated terminal secretory units, the acini, connected to an array of ducts
that empty into the principal excretory duct and the oral cavity (Figure 1a, E18.5). The SMG
undergoes another round of morphogenesis and cytodifferentiation during the postnatal
period to give rise to an adult gland three weeks after birth.
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tAccurate assembly and regulation of E-cadherin junctions are critical for the
cytodifferentiation of SMGs (15, 16, 27, 28). Since E-cadherin-mediated cell adhesion
directs the localization and activity of the Hippo pathway effectors TAZ and YAP (18,22),
we sought to determine whether Hippo signaling had a role in SMG development at three
embryonic stages representing early morphogenesis (E13.5), initial cytodifferentiation
(E15.5) and late cytodifferentiation (E18.5). At these stages, E-cadherin junctions undergo
dynamic changes in organization, with increasing levels of associated α-catenin indicating
junction maturation (16). Further, TAZ and YAP transcripts are detected at these embryonic
stages of development (http://sgmap.nidcr.nih.gov/sgmap/sgexp.html), with TAZ transcripts
displaying high abundance. Therefore, to investigate changes in Hippo pathway activity
during SMG embryonic development, we focused our initial analysis on TAZ expression
and phosphorylation. Immunoblot analyses showed that the abundance of TAZ increased
with cytodifferentiation (Figure 1b, *p<0.05). This was associated with progressively higher
levels of phospho-TAZ from E13.5 to E18.5 (Figure 1c, *p<0.05). Comparison of the ratios
of phospho-TAZ to total TAZ revealed an increase in the phosphorylation levels at later
developmental stages (Figure 1d). Thus, cytodifferentiation of SMGs is accompanied by
increased levels and phosphorylation of TAZ, suggesting that Hippo pathway signaling
plays a role in the establishment and/or maintenance of acinar and ductal cell polarity.
To further examine the roles of TAZ in SMG morphogenesis, we followed the expression
and localization of TAZ at different stages of embryonic development by
immunofluorescence localization coupled with confocal microscopy. Our previous studies
identified two populations of salivary cell progenitors early in SMG morphogenesis: an
outer layer of polarized acinar progenitors and a population of ductal progenitors in the inner
bud regions (16). Interestingly, TAZ was differentially distributed in acinar and ductal
progenitors early in morphogenesis at E13.5. In the polarized pro-acinar cell layer in contact
with the basement membrane, which contains well-organized E-cadherin junctions, TAZ
was found at the cell-cell borders (Figure 1e, E13.5, top insets, arrows), suggesting that
TAZ is associated with E-cadherin junctions in these cells. We have also shown that during
SMG morphogenesis, the acinar progenitors surround a population of proliferating
polymorphous ductal progenitors with poorly organized E-cadherin junctions in the distal
regions of the terminal buds, while the proximal region of the glands contain cells already
forming secondary ductal structures. These secondary ductal structures extend the primary
duct from the stalk region into the newly forming terminal buds, a process during which a
subset of immature ductal progenitors cease to proliferate and undergo reorganization into
ductal structures through cytoskeletal rearrangements as delineated by robust staining of F-
actin (16). Examination of the distribution of TAZ in the inner bud region comprising ductal
progenitors revealed that TAZ was predominantly cytoplasmic, with an exception for a
fraction localized to the sites of new duct formation as marked by F-actin in the proximal
bud regions (Figure 1e, E13.5, arrows, lower insets). Additionally, TAZ was detected in the
mesenchyme surrounding the epithelial buds.
During morphogenesis at E15.5, the acinar progenitors continue to expand and ultimately
form unit acinar structures by the end of cytodifferentiation at E18.5. Development of the
ductal tree moves from the proximal to distal regions of the terminal buds and involves the
specification of apical membranes by F-actin and interacting components (16).
Immunofluorescence localization of TAZ at E15.5 revealed that it continued to localize at
intercellular junctions in the acinar progenitor cells (Figure 1e, E15.5, outer cell layer,
arrows). Moreover, TAZ was more prominently defined in the newly forming duct regions,
where it colocalized with F-actin (Figure 1e, E15.5, arrows, insets). Interestingly, at this
stage, TAZ was present in both the cytoplasm and nucleus (Figure 1f, arrows, X-Y and
orthogonal X-Z sections). Late in embryonic cytodifferentiation at E18.5, TAZ was
organized at intercellular junctions in differentiated acinar and ductal cells (Figure 1e,
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tE18.5, arrows, insets). We note that a significant fraction of TAZ was localized to sites
representing either the basal regions of the SMG epithelium and/or the adjacent
myoepithelial and mesenchymal compartments. Collectively, these data show that SMG
development is associated with increased levels of phosphorylated and junctional TAZ in
differentiating acinar and ductal cells.
TAZ interacts with E-cadherin junctional complexes in a development-dependent manner
Hippo pathway signaling is induced by cadherin-based adhesion signals, with TAZ and YAP
binding to E-cadherin and α-catenin promoting TAZ and YAP cytoplasmic localization (25,
29, 30). Therefore, we investigated whether increased TAZ at cell-cell borders during SMG
cytodifferentiation reflects increased binding to E-cadherin and/or α-catenin. Co-
immunoprecipitation (co-IP) studies revealed that TAZ was present in E-cadherin
complexes at E15.5, and that its association with E-cadherin increased at E18.5 (Figure 2a).
This coincided with a more focused organization of E-cadherin at cell-cell-cell borders at
E18.5, previously shown to indicate mature AJs (Figure 2c, arrows, insets) (14, 20).
Likewise, co-IP of TAZ complexes revealed that TAZ associated with augmented levels of
α-catenin at E18.5 compared to E15.5 (Figure 2b), which coincided with increased
recruitment of α-catenin to cell-cell borders (Figure 2d, arrows, insets). We have previously
shown that increased presence of α-catenin at the membrane reflects its association with
mature E-cadherin junctions (16). Furthermore, immunofluorescence analysis of SMGs
doubly stained for TAZ and α-catenin revealed increased co-localization from E15.5 to
E18.5 (Figure 2e, arrows, insets). Thus, as E-cadherin junctions mature, TAZ associates
with E-cadherin/α-catenin complexes, suggesting that TAZ has a role in E-cadherin junction
maturation during SMG morphogenesis.
Inhibition of the Hippo pathway Lats2 kinase perturbs SMG branching morphogenesis
Activation of Lats kinases leads to phosphorylation and subsequent nuclear exclusion of
TAZ and YAP, whereas inhibition of Lats kinase activity reduces TAZ and YAP
phosphorylation, resulting in increased TAZ and YAP nuclear localization (21). Lats2
expression is high in developing SMGs (http://sgmap.nidcr.nih.gov/sgmap/sgexp.html).
Thus, to further assess the role of Hippo signaling in SMG development, we examined the
consequences of inhibiting Lats2 kinase in E13.5 ex vivo organ cultures on branching
morphogenesis.
Treatment of E13.5 SMG organ cultures with siRNA to Lats2 kinase for 48 h resulted in a
30% reduction in Lats2 transcript levels in silenced (S) glands compared to non-silenced
(NS) controls (Figure 3a). In these studies, we also followed the uptake of siRNA by Block-
iT™, a small fluorescein- tagged oligonucleotide (Figure 3b). Results showed that the
polarized outer acinar progenitor cell layer and the differentiating duct cells in the stalk
region did not label extensively with Block-iT™, suggesting that Lats2 siRNA-mediated
knockdown may not be efficient in these cells (Figure 3b, arrows). In contrast, the ductal
progenitors, including the reorganizing cells in the proximal bud regions, displayed a robust
staining for Block-iT™, suggesting that siRNA-mediated knockdown of Lats2
predominantly occurred in these cells (Figure 3b). This differential uptake of Block-iT™ by
cells in the developing SMG may explain the observed modest decrease in Lats2 mRNA
levels following siRNA treatment. Nonetheless, even a 30% downregulation of Lats2
mRNA coincided with distinct morphological changes that included a flattened central area
in the main branching region, larger endbuds and diminished overall branching (Figure 3c).
The flattening of the glands reflects inhibition of ductal extensions, most likely due to the
failure of cells in the duct forming regions to differentiate, which is required for subsequent
cellular rearrangements, consistent with the proliferation promoting activity of TAZ/YAP.
Indeed, morphometric measurements revealed that partial inhibition of Lats2 kinase leads to
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3d, **p<0.01). Although Ki67 staining of cells in the reorganizing duct region was not
easily discernible, the Lats2-inhibited glands displayed increased proliferation in the outer
layer (Fig. 3e).
Our previous studies have demonstrated that F-actin demarks newly forming ductal
structures in proximal areas of terminal buds (16). While the sites of new duct formation
contained tight F-actin cables in NS buds, in the Lats2-inhibited glands, some regions
exhibited dispersed patterns of F-actin distribution in the proximal branching regions (Figure
3f, arrows, F-actin, NS and S). Such expanded patterns of F-actin distribution in Lats2-
inhibited glands suggested that in the absence of Hippo signaling, duct initiation occurred
but that its extension did not proceed normally. Therefore, Hippo signaling is necessary for
proper secondary duct development during SMG branching morphogenesis.
We have previously reported that during duct development, E-cadherin is well organized at
the apical lateral surfaces of differentiating duct cells and serves as a survival signal (16). In
Lats2-silenced glands, E- cadherin displayed altered organization in the prospective duct
regions (Figure 3f, arrows, E-cadherin NS and S). Likewise, while in NS glands TAZ
exhibited a well-defined and focused co-localization with F-actin at the apical domains of
newly forming duct regions, in Lats2-silenced glands, its organization was irregular and
spread out, although it still followed the patterns of F-actin (Figure 3f, arrows, TAZ & F-
actin, merge, NS and S). This suggested that cells in which Lats2 was inhibited did not
undergo reorganization into secondary ductal structures, thus failing to extend the ductal
axes into the expanding gland. Further, the staining of TAZ in Lats2-inhibited glands was
more diffuse in cells destined for reorganization, suggesting that TAZ was re-localized from
junctions to the nucleus (Figure 3g, dashed arrows). Collectively, these data showed that
Hippo pathway Lats2 kinase plays a crucial role in secondary duct formation during SMG
branching morphogenesis.
SMGs from NOD mice display dysmorphogenesis coupled with altered expression of TAZ
and E-cadherin junctional components
The NOD mouse has been used extensively as a model of SS, as the diseases in mice show
many similarities to the human disease in terms of immunology, affected organs and gender
predisposition (31). Given our observations linking the Hippo pathway to salivary gland
development, we next investigated the expression of TAZ in NOD mice, as this mouse
model is known to have structural defects in several organs and to develop SS-like disease
(8). We first examined the gross morphology of SMGs from NOD mice and compared them
to SMGs from wild type, CD1, mice. Already at E13.5, SMGs from NOD mice displayed a
broader initial branching region, and at E14.5, they exhibited a significantly more flattened
morphology with less branching than the wild type glands, resembling Lats2-silenced glands
(Figure 4a). At E15.5, NOD SMGs had larger terminal buds, and they lacked the three-
dimensional budding pattern typical of wild type glands. These altered morphological
features and growth characteristics were also evident at E18.5, with NOD glands displaying
less compact morphology and diminished branching (Figure 4a).
Examination of E-cadherin junctional components in NOD SMGs revealed dramatic
changes in their abundance at all three stages of embryonic morphogenesis. E-cadherin
levels were significantly decreased in developing NOD glands at stages E15.5 and E18.5
(Figure 4b), and while the levels of α-catenin were higher in E13.5 NOD glands than in their
wild type counterparts, they declined with cytodifferentiation at E15.5 and E18.5 (Figure
4c). Interestingly, IQGAP1 was more prominent in NOD SMGs at E18.5, suggesting that
diminished E-cadherin adhesion is associated with increased expression of this junction
destabilizer (Figure 4d)(32). The most dramatic changes in NOD SMGs, however, were
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tdetected for TAZ and its phosphorylated species. While at E13.5, levels of TAZ were
similar between wild type and NOD SMGs, they were greatly diminished at later stages of
cytodifferentiation in the NOD glands. This pattern was also observed for the
phosphorylated form of TAZ, with a dramatic reduction in phospho-TAZ in NOD glands
already apparent at E13.5 (Figure 4e & f). Loss of phospho-TAZ early in morphogenesis
correlated with the defective branching morphology of E13.5 NOD SMGs. These findings
further support a role for TAZ in proper morphogenesis and cytodifferentiation of the SMG.
NOD SMGs exhibit defects in duct formation
Because expression levels of E-cadherin and α-catenin are greatly diminished in embryonic
NOD SMGs undergoing cytodifferentiation, it was not possible to assess the interactions
between TAZ and E-cadherin junctions by co-IP. To gain insight into the quality of E-
cadherin junctions in NOD SMGs, we investigated E-cadherin localization by indirect
immunofluorescence at E15.5, an embryonic stage at which pronounced differences in the
abundance of E-cadherin and α-catenin are detected by immunoblots between wild type and
NOD SMGs. Whereas E-cadherin displayed apical-lateral organization in columnar cells in
the duct forming region of wild type glands, in SMGs from NOD mice, its distribution at the
apical-lateral domains was less focused, coincident with the loss of columnar morphology
and expansion of duct forming regions. (Figure 5a, arrows, E-cadherin). A similar aberrant
pattern of distribution was also found for F-actin in NOD SMGs (Figure 5a, arrows, F-
actin). Likewise, while a fraction of TAZ was found at the apical domains of cells in the
branching ductal region in wild type glands, its localization was more diffuse in NOD
SMGs, which also correlated with disorganized and broader distribution of F-actin (Figure
5b, arrows, TAZ & F-actin). Specifically, although TAZ was detected in the newly forming
duct regions in both NOD and wild type SMGs, in NOD glands, the proximal extension of
F-actin cables into the bud was compromised. This coincided with expanded and not tightly
organized F-actin staining in NOD glands compared to CD1 glands (Figure 5b, arrows, F-
actin). Importantly, the disorganization of F-actin in NOD SMGs was similar to that in the
Lats2-inhibited glands (Figure 3f & g). The observations that both Lats2-inhibited and NOD
SMGs display aberrant duct formation and defects in apical-basal polarity in the
reorganizing secondary duct cells suggest that the NOD phenotype is associated with
dysregulation of Hippo pathway activity.
Deregulation of Hippo signaling, loss of cell polarity and ECM remodeling are features of
SS
To determine whether the results from the mouse models are conserved in human SS tissues,
we evaluated human labial biopsy specimens from patients with SS for E-cadherin and its
junctional binding partners, β-catenin and α-catenin, as well as for the Hippo effectors TAZ
and YAP by immunofluorescence analyses and compared them to tissue specimens from SS
non-compatible (non-SS) individuals. Hematoxylin and Eosin (H&E) staining of non-SS
specimens revealed well-preserved tissue architecture (Figure 6a, i). In contrast, SS tissues
displayed various degrees of secretory tissue loss and lymphocytic infiltration depending on
the severity of the disease, as determined by the focus score (Figure 6a, ii-iv). For instance, a
biopsy with a focus score 1 was positive for a germinal center (GC), reflecting the
organization of lymphocytes into foci, known as tertiary lymphoid tissue, and thought to be
a predictor for lymphoma development (Figure 6a, ii). Regions in the middle of lymphocytic
infiltration had dilated ducts, although areas without foci also had lymphocytic cells
surrounding the acini (Figure 6a, iii). The biopsy with a focus score 5.4 was also GC
positive, but in spite of the “high” focus score and prominent level of infiltration, this gland
still maintained tissue integrity (Figure 6a, iv). It is important to note that all
immunofluorescence imaging was taken from regions distal to the lymphocytic infiltrations
to ensure that they did not affect salivary epithelial cells in these analyses (Figure 6a, iii).
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and its associated catenins confirmed well-organized E-cadherin junctions in acinar and
ductal epithelia (Figure 6b-d, arrows, insets, Non-SS). In contrast, SS glands showed
disrupted distribution of E-cadherin (Figure 6b, arrow, SS). Reduced E-cadherin adhesion in
SS specimens was further confirmed by diminished immunofluorescence staining of β- and
α-catenins at lateral borders compared to non-SS controls (Figures 6c, d, arrows).
Concomitant with the loss of α-catenin from cell-cell junctions, labial salivary glands from
SS patients displayed elevated immunostaining of IQGAP1, known to destabilize E-cadherin
adhesion and to function in signaling processes promoting proliferation and ECM
remodeling (Figure 6e, arrow)(32). These structural changes in E-cadherin junctions were
associated with deregulation of the downstream effectors of Hippo, TAZ and YAP. In SS
tissues, both TAZ and YAP were lost from lateral cell borders and were instead localized to
the basal regions that coincided with the nuclei (Figure 6f & g, respectively, arrows, SS).
This resembled the scenario in NOD SMGs, which displayed upregulation of IQGAP1 (Fig.
4d). Significantly, nuclear redistribution of TAZ and YAP in SS specimens correlated with
stronger immunostaining of CTGF, a downstream transcriptional target of TAZ and YAP
(Figure 6h) and a known regulator of ECM-remodeling and inducer of fibrosis (33).
Moreover, SS patient biopsies exhibited increased deposition of fibronectin, another
potential downstream target of TAZ and YAP, confirming ECM remodeling in these tissues
(Figure 6i, arrow).
Discussion
As a complex autoimmune disease, SS has remained recalcitrant to the identification of key
factors and processes responsible for its development and pathophysiology. While defects in
the immune system have long been considered to be a cause of SS, recent studies have
highlighted loss of cell polarity and structural integrity to have a major role in its etiology.
Results presented here further support the hypothesis that loss of salivary cell junctional
integrity plays a critical role in SS and suggest that the Hippo signaling pathway, in
particular, is a key player in this disease. We provide evidence that a Hippo effector, TAZ,
interacts with two major determinants of cellular polarity, E-cadherin and α-catenin, and
that this interaction is required for normal cytodifferentiation and organization of acinar and
ductal structures. Significantly, dysregulation of Hippo signaling is a feature of SMGs from
NOD mice and of labial specimens from human SS patients, suggesting that defects in
Hippo signaling are associated with this disease.
Increasing evidence implicates structural defects as a primary contributor to SS and
autoimmunity. In NOD mice, an animal model for SS and Type 1 diabetes, regeneration of
target organs with exogenous stem cells restores the normal morphology of both SMGs and
pancreatic islets, making them resistant to disease (34). Earlier studies suggest that the onset
of autoimmunity in NOD mice may result from developmental defects, as normally
developed SMGs from NODs evade autoimmune exocrinopathy (35). Also, structural
defects and hypo-salivation in NOD salivary glands can occur independent of lymphocytic
infiltration (8, 36). Recent findings from patients with SS also indirectly support the premise
that the immune system may not be the only culprit for salivary gland dysfunction. Some
hypo-functional salivary glands from SS patients display acinar cell atrophy, loss of E-
cadherin junctions, mislocalization of proteins, dilated ducts and remodeling of the
extracellular matrix (ECM), and the extent of such pathology, including the degree of
secretory defects, does not always correspond to the level of lymphocytic infiltrations
(37-39). Therefore, at least in some patients, defective secretion and autoimmunity are not
linked (1, 40).
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tDuring SMG embryonic development, we observed the Hippo pathway effector, TAZ, to be
localized at cell-cell junctions in the polarized acinar progenitor cell layer. Moreover, in the
newly forming secondary duct regions, a fraction of TAZ changed distribution from diffuse
in the cytoplasm to a more focused organization at intercellular junctions where it co-
localized with F-actin. This junctional localization of TAZ is supported by the observed
increases in TAZ phosphorylation during embryonic branching morphogenesis. Moreover,
co-localization of TAZ with F-actin in duct forming regions coincided with a progressive
increase in the interaction of TAZ with E-cadherin and α-catenin. Taken together, these
observations suggest a role for junctional TAZ in defining polarity in secondary duct cells.
Consistent with this idea, knockdown of Lats2 altered the localization of TAZ and resulted
in defects in branching morphogenesis and in the formation of secondary ductal structures.
Moreover, NOD embryonic SMGs displayed similar features as the Lats2 siRNA-treated
glands, providing evidence that deregulation of the Hippo pathway may contribute to
structural defects in the NOD SMG. We also note that at E15.5, a fraction of TAZ was
nuclear, supporting its role as a transcriptional co-activator of genes involved in remodeling
the ECM at this stage of SMG cytodifferentiation (41). Further, a pool of TAZ was localized
to the basal layer and the surrounding mesenchymal/myoepithelial regions, suggesting an
unexplored non-junctional and non-nuclear role for TAZ during SMG development. Our
findings resemble studies demonstrating the importance of TAZ in normal alveolarization of
lungs in mice, another tissue that develops through branching morphogenesis (42).
E-cadherin plays a pivotal role in the establishment of cell polarity in epithelial tissues. Our
previous studies have documented that cytodifferentiation of the SMG is accompanied by
increased interactions between α-catenin and E-cadherin (16). Cellular localization of YAP,
a paralog of TAZ, is regulated by binding to E-cadherin and α-catenin (22-24). Here, we
demonstrate that like YAP, TAZ is associated with α-catenin and E-cadherin complexes,
suggesting similar regulation of its subcellular localization. Interactions between TAZ and
E-cadherin complexes in the SMG are likely to be mediated by α-catenin, although it is also
possible that a fraction of α-catenin associates with TAZ independently of E-cadherin. The
increase in the interactions of TAZ with E-cadherin and α-catenin with SMG
ctyodifferentiation strongly suggests that the Hippo pathway is important for maintaining
junctional integrity and polarity during SMG branching morphogenesis. Importantly, human
labial SS tissues exhibit structural defects in the acini and ducts with the loss of E-cadherin
and its associated junctional partners. This is consistent with the reduced E-cadherin and
altered cell polarity reported in other SS studies (37, 43-45). Defects in cell polarity in SS
may impact Hippo signaling that will ultimately affect downstream transcriptional events.
Alternatively, inhibition of Hippo signaling may drive aberrant localization of TAZ to the
nucleus and alter transcription, leading to extracellular matrix remodeling. Since TAZ
functions as a transcriptional co-activator of CTGF, a key factor contributing to tissue
fibrosis, regulation of its subcellular localization is likely to play an important role in SS.
Indeed, in the mature SMG, cells in the intercalated duct regions immediately adjacent to the
acini are thought to function in acinar cell replacement during tissue renewal. Thus, defects
in ductal cell polarity may play a role later in adult tissue homeostasis and be exacerbated by
hormonal conditions and/or environmental insults, potentially explaining the frequently
observed late onset of this disease.
When examining patients with different degrees of inflammation, we found tissue integrity
among the biopsies to be largely heterogeneous, with structural defects evident in regions of
the glands not adjacent to infiltrates. Although loss of structural integrity has been linked to
hypo-secretion in some SS cases, its role in increased susceptibility to lymphocytic
infiltrations has not been explored. Interestingly, ablation of E-cadherin junctional protein,
α-catenin, has been shown to drive lymphocytic infiltration both in a mouse model and in a
Enger et al. Page 11
Lab Invest. Author manuscript; available in PMC 2014 May 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tvariety of cancers (46-48). Further studies are needed to determine how structural defects
and loss of polarity in the SMG may lead to increased susceptibility to autoimmune reaction.
To date, the etiology of SS remains controversial, and a common etiopathogenic model
involves genetic predispositions triggered by environmental, pathological and
immunological factors that drive clinical manifestations, where loss of secretory function is
believed to result from cytotoxicity caused by progressive lymphocytic infiltration (50).
Here, we provide a molecular explanation for at least a subset of SS cases by demonstrating
that the dysregulation of the Hippo pathway and associated tissue structural integrity may be
an underlying basis of this disease.
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Expression and localization of TAZ during submandibular gland (SMG) embryonic
development. (a) Phase microscopy images of CD1 mice epithelial buds (e) and surrounding
mesenchyme (m) isolated from embryonic days E12.5-E18.5 during SMG branching
morphogenesis. Size bar: 20 μm. (b) Immunoblot of TAZ SMG expression levels at E13.5,
E15.5 and E18.5. Bar graph, Fold change in TAZ levels after normalization to GAPDH,
*p<0.05. (c) Immunoblot of p-TAZ expression levels at E13.5, E15.5 and E18.5. Bar graph,
Fold change in p-TAZ levels after normalization to GAPDH, *p<0.05. (d) Ratio of p-TAZ
to total TAZ at E13.5, E15.5 and E18.5. (e) Immunofluorescence localization of SMG TAZ
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t(green) at E13.5, E15.5 and E18.5, counterstained with F-actin (red). (f)
Immunofluorescence localization of TAZ (green) at E15.5, counterstained with nuclei
(blue).
Enger et al. Page 16
Lab Invest. Author manuscript; available in PMC 2014 May 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 2.
TAZ interacts with E-cadherin junctional complexes throughout development. (a) E-
cadherins were immunoprecipitated from E15.5 and E18.5 SMG tissue lysates and their
interaction with TAZ was assessed by immunoblot. Bar graph, Quantification of TAZ/E-
cadherin levels. (b) TAZ was immunoprecipitated from E15.5 and E18.5 SMG tissue lysates
and its interaction with α-catenin was examined by immunoblot. Bar graph, Quantification
of α-catenin/TAZ levels. (c) Immunofluorescence localization of E-cadherin at E.15.5 and
E18.5. Size bar: 20 μm. (d) Immunofluorescence localization of α-catenin at E.15.5 and
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tE18.5. Size bar: 20 μm. (e) Immunofluorescence co-localization of α-catenin (red) and TAZ
(green) at E15.5 and E18.5. Size bar: 20 μm.
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tFigure 3.
Inhibition of Lats2 kinase perturbs SMG branching morphogenesis. (a) Quantitative PCR of
Lats2 transcript levels in non-silenced (NS) or Lats2 silenced (S) glands. **p<0.01. (b)
Immunofluorescence localization of BLOCK-iT™ Fluorescent Oligo, a marker of
transfection efficiency (green) counterstained with F-actin (red). (c) Phase microscopy
images of NS and S SMGs transfected at stage E13.5 at 0h and 48h after Lats2 inhibition.
(d) Morphometric analyses of the number of buds at 48h/0h (top) and area of buds at 48h/0h
(bottom) of NS and S SMGs. **p<0.01. (e) Immunofluorescence localization of Ki67
(green), counterstained with F-actin (red) and nuclei (blue), in NS and S glands. Size bar:
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t20μm. (f) Immunofluorescence localization of E-cadherin (green), counterstained with F-
actin (red), in NS and S glands. Size bar: 20μm. (g) Immunofluorescence localization of
TAZ (green), counterstained with F-actin (red), in NS and S glands. Size bar: 20 μm.
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NOD mouse SMGs display dysmorphogenesis and altered expression levels of TAZ and E-
cadherin junctional components. (a) Phase microscopy images of SMGs isolated from NOD
mice on embryonic days E13.5-E18.5 during SMG branching morphogenesis. Size bar: 20
μm. (b) Immunoblots comparing E-cadherin expression levels in CD1 and NOD SMGs at
E13.5, E15.5 and E18.5. Bar graph, Fold change in E-cadherin levels after normalization to
GAPDH, *p<0.05. (c) Immunoblots assessing α-catenin expression levels in CD1 and NOD
SMGs at E13.5, E15.5 and E18.5. Bar graph, Fold change in α-catenin levels after
normalization to GAPDH. (d) Immunoblots comparing IQGAP1 expression levels in CD1
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tand NOD SMGs at E13.5, E15.5 and E18.5. Bar graph, Fold change in IQGAP1 levels after
normalization to GAPDH. (e) Immunoblots comparing TAZ expression levels in CD1 and
NOD SMGs at E13.5, E15.5 and E18.5. Bar graph, Fold change in TAZ levels after
normalization to GAPDH, *p<0.05. (f) Immunoblots comparing p-TAZ expression levels in
CD1 and NOD SMGs at E13.5, E15.5 and E18.5. Bar graph, Fold change in p-TAZ levels
after normalization to GAPDH, *p<0.05.
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NOD SMGs have aberrant duct formation and disorganized E-cadherin and TAZ. (a)
Immunofluorescence localization of E-cadherin (green) in CD1 and NOD mouse SMGs at
stage E15.5, counterstained with F-actin (red). Size bar: 20 μm. (b) Immunofluorescence
localization comparing TAZ (green) in CD1 and NOD mouse SMGs at stage E15.5,
counterstained with F-actin (red). Size bar: 20 μm.
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tFigure 6.
Sjogren's syndrome (SS) compatible labial gland biopsies display loss of polarity,
dysregulated Hippo signaling and ECM remodeling. (a) Hematoxylin and Eosin (H & E)
staining of a biopsy from an SS non-compatible (Non-SS) patient compared to different
degrees of lymphocytic infiltrations (measured as the focus score) of SS patients. Size bar:
50 μm. (b) Immunofluorescence localization of E-cadherin in SS and Non-SS glands,
counterstained with DAPI. Size bar: 20 μm. (c) Immunofluorescence analyses of β-catenin
in SS and Non-SS glands, counterstained with DAPI. Size bar: 20 μm. (d)
Immunofluorescence localization of α-catenin in SS and Non-SS glands, counterstained
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twith F-actin. Size bar: 20 μm. (e) Immunofluorescence localization of IQGAP1 in SS and
Non-SS glands, counterstained with DAPI. Size bar: 20 μm. (f) Immunofluorescence
localization of TAZ in SS and Non-SS glands (left panel), counterstained with DAPI (right
panel). Size bar: 20 μm. (g) Immunofluorescence localization of YAP in SS and Non-SS
glands (left panel), counterstained with DAPI (right panel). (h) Immunofluorescence
localization of CTGF in SS and Non-SS glands. Size bar: 20 μm. (i) Immunofluorescence
localization of fibronectin in SS and Non-SS glands. Size bar: 20 μm.
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